PPAR active compounds

Details PPAR active compounds PPAR active compounds

2004-09-08

2008-03-25

Anderson, Rebecca (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S310000, C514S313000, C514S339000, C514S415000

Reexamination Certificate

active

07348338

ABSTRACT:
Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile.

REFERENCES:
patent: 3489767 (1970-01-01), Yamamoto et al.
patent: 4150949 (1979-04-01), Smith
patent: 4568649 (1986-02-01), Bertoglio-Matte
patent: 4626513 (1986-12-01), Burton et al.
patent: 5283251 (1994-02-01), Okada et al.
patent: 5466689 (1995-11-01), Yamamoto et al.
patent: 5747276 (1998-05-01), Hoch et al.
patent: 5763198 (1998-06-01), Hirth et al.
patent: 5840485 (1998-11-01), Lebl et al.
patent: 5877007 (1999-03-01), Housey
patent: 6090912 (2000-07-01), Lebl et al.
patent: 6178384 (2001-01-01), Kolossvary
patent: 6243980 (2001-06-01), Bronstein et al.
patent: 6288234 (2001-09-01), Griffin
patent: 6294330 (2001-09-01), Michnick et al.
patent: 6329389 (2001-12-01), Suzuki et al.
patent: 6337344 (2002-01-01), Defossa et al.
patent: 6635655 (2003-10-01), Jayyosi et al.
patent: 7202266 (2007-04-01), Arnold et al.
patent: 2004/0006071 (2004-01-01), Simoneau et al.
patent: 2005/0004115 (2005-01-01), Sharma et al.
patent: 0 154 734 (1990-08-01), None
patent: 1219595 (2002-07-01), None
patent: 1285908 (2003-02-01), None
patent: 1661879 (2006-05-01), None
patent: WO91/13060 (1991-09-01), None
patent: WO9113060 (1991-09-01), None
patent: WO96/04906 (1996-02-01), None
patent: WO 2002/030863 (2002-04-01), None
patent: WO 2004/007439 (2004-01-01), None
patent: WO 2004/056740 (2004-07-01), None
patent: WO 2005/037763 (2005-04-01), None
patent: WO 2005/044787 (2005-05-01), None
patent: WO 2005/054176 (2005-06-01), None
Chang, et al., “Substituted Imidazoles as Glucagon Receptor Antagonists,” Bioorganic and Medicinal Chem. Lett., vol. 11, pp. 2549-2553 (2001).
Corton et al., “Perioxisome Proliferator-Activated Receptors: Mediators of Phthalate Ester-Induced Effects in the Male Reproductive Tract?” Toxicological Sciences 83, pp. 4-)7 (2005).
Buchan, K., et al. Med. Res. Rev., 20, No. 5, pp. 350-366 (2000).
VanZandt, et al. J. Med. Chem. 48, pp. 3141-3152 (2005).
Mahindroo et al. J. Med. Chem., 48, pp. 8194-8208 (2005).
Chang, et al. “Substituted Imidazoles as Glucagon Receptor Antagonist” Bioorg. & Med. Chem. Letrs., 11, pp. 2549-2553 (2001).
Trost et al. “2-Alkoxybenzo-1,3-dithiole 1,1,3,3-tetraoxide. A carbonyl 1,1-dipole synthon.” J. Am. Chem. Soc., vol. 106(8), pp. 2469-2471 (1984).
Yato et al. “Reduction of Carboxylic Esters with Triethyl Silane in the Combined use of Titanium Tetrachloride and Trimethylsilyl Trifluoromethanesulfonate.” Tetrahedron, vol. 57, pp. 5353-5359 (2001).
Trost et al., “2-Alkoxybenzo-1,3-dithiol 1,1,3,3-tetraoxide. A carbonyl 1,1-dipole synthon,” JACS, vol. 106(8), pp. 2469-2471 (1984).
Davis et al., A convenient synthesis of bisindoyl- and indolylaryl- maleic anhydrides. Tetahedron Letters, 31:2353-2356, 1990.
Holzapfel and Olivier, The synthesis of a γ-keto-α-amino acid, a key intermediate in the synthesis of monatin, a new natural sweetener. Synthetic Communications, 23(18): 2511-26, 1993.
Ketcha et al., Synthesis of alkyl-substituted N-protected indoles via acylation and reductive deoxygenation. J. Organic Chemistry, 54(18): 4350-4356, 1989.
Chang, et al., Substituted imidazoles as glucagons receptor antagonists. Bioorg. And Med. Chem. Letters, 11:2549-2553, 2001.
The International Search Report and the Written Opinion of the International Searching Authority for PCT Application No. PCT/US2004/23234 dated Nov. 1, 2004.
Aldred, et al., “Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas,”Oncogene22:3412-3416 (2003).
Alfthan, “Surface Plasmon Resonance Biosensors as a Tool in Antibody Engineering,”Biosensors&Bioelectronics13:653-63 (1998).
Al-Obeidi, “Peptide and Peptidomimetic Libraries—Molecular Diversity and Drug Design,”Mol Biotechnol9(3):205-223 (1998).
Amersdorfer and Marks, “Phage Libraries for Generation of Anti-Botulinum scFv Antibodies,”Methods in Molecular Biology145:219-40 (2001).
Azimov, et al., “Nucleophilic Substitution Reactions in 6-Chlor-5-Azaindolines,”Chem. Heterocycl. Compd.17(12):1208-1216 (1981).
Bartlett et al., “CAVEAT: A Program to facilitate the structure-derived design of biologically active molecules.” In Molecular Recognition: Chemical and Biological Problems. The Proceedings of an International Symposium, University of Exeter, Apr. 1989,Royal Society of Chemistry, Cambridge 182-196 (1989).
Bagshaw and Harris, “Measurement of Ligand Binding to Proteins,”Spectrophotometry and Spectrofluorometry: A Practical Approach4:91-114 (1987).
Bell, “Spectroscopy in Biochemistry,”CRC PressI:155-194 (1981).
Belletire, J.L., “Acylcyanamides: Versatile Synthetic Intermediates,”Synthetic Communications18:2063-2071 (1988).
Berger and Wagner, “Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors,”Diabetes Technology&Therapeutics4:163-174 (2002).
Boehm, et al., “Novel Inhibitors of DNA Gyrase: 3D Structure Based Biased Needle Screening, Hit Validation by Biophysical Methods, and 3D Guided Optimization. A Promising Alternative to Random Screening,”J. Med. Chem.43:2664-2674 (2000).
Bohacek, et al., “Multiple Highly Diverse Structures Complementary to Enzyme Binding Sites: Results of Extensive Application of ade NovoDesign Method Incorporating Combinatorial Growth,”J. Am. Chem. Soc.116:5560-5571 (1994).
Böhm, “On the Use of LUDI to Search the Fine Chemicals Directory for Ligands of Proteins of Known Three-Dimensional Structure,”J. Comp. Aided Molec. Design8:623 (1994).
Bolger and Sherman, “Computer Modeling of Combing Site Structure of Anti-Hapten Monocional Antibodies,”Methods Enz.203:21-45 (1991).
Brenner et al., “Encoded Combinatorial Chemistry,”Proc. Natl. Acad. Sci. USA89:5381-5383 (1992).
Buchheit, et al., “The Serotonin 5-HT4Receptor. 2. Structure—Activity Studies of the Indole Carbazimidamide Class of Agonists,”J. Med. Chem.38:2331-2338 (1995).
Burstein, et al., “Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: a Phase II Study,”Breast Cancer Research and Treatment79:391-397 (2003).
Bychikhina, et al., “Electrophilic Substitution Reactions in 1-Benzyle-6-Methoxy-7-Cyano-5-Azaindole and 6-Oxo-5-Azaindoline,”Chemistry of Heterocyclic Compounds18:268-271 (1982).
Cantello, et al., “[[a-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents,”J. Med. Chem.37:3977-3985 (1994).
Cao, et al., “Dual Probes for the Dopamine Transporter and σ1Receptors: Novel Piperazinyl Alkyl-bis(4′-fluorophenyl)amine Analogues as Potential Cocaine-Abuse Therapeutic Agents,”J. Med. Chem.46:2589-2598 (2003).
Carell et al., “New Promise in Combinatorial Chemistry: Synthesis, Characterization, and Screening of Small-Molecule Libraries Solution,”Chem. Biol.3:171-183 (1995).
Chabala, “Solid-Phase Combinatorial Chemistry and Novel Tagging Methods for Identifying Leads,”Curr Opin Biotechnol6(6):633-9 (1995).
Checovich et al., “Fluorescence Polarization—a New Tool for Cell and Molecular Biology,”Nature375:254-256 (1995).
Cheung, et al., “Synthesis of 2-chloro-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one,”Tetrahedron Letters42:999-1001 (2001).
Chong, et al., “Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7,”PNAS96:14330-14335 (1999).
Clark et al., “PRO—LIGAND: An Approach to De Novo Molecular Design. 1. Application to the Design of Organic Molecules,”J. Comp. Aided Molec. Design9:13-32 (1995).
Coe et al.

Affiliated with

Also associated with

Rating

PPAR active compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PPAR active compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PPAR active compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3969302